BioMarin to pay $4.8B for Amicus and its rare disease drugs

BioMarin plans to dish out $4.8 billion to acquire Amicus Therapeutics and its two approved rare disease medicines, the California biotech said Friday. By gaining access to Amicus' meds for Pompe ...